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Summary--The ACTH response to arginine vasopressin was the same in patients with depression 
while cortisol response was significantly greater in patients with depression when compared to the 
control population. These findings are consistent with the hypothesis that vasopressin corticotroph 
receptors are not downregniated in depression and that there is increased adrenal responsiveness 
in patients with depression to endogenous ACTH. 
INTRODUCTION 
ABNORM~ITmS of the hypothalmic-pltuitary-adrenal (HPA) axis in patients with major 
depressive disorder have been well described (SACB_~at et al., 1973; C~tt~ato~ et al., 1981; 
SC~ESSER et aL, 1981). Much research has focused on suppression of the HPA axis with 
dexamethasone; however, few investigators have studied ACTH and cortisol response to 
vasopressin in affective illness. 
Vasopressin is a nonapeptide which is known to stimulate the pituitary-adrenal axis 
in rats (McC~'~N and BROB~K, 1959) and in humans (McDoNALD and WEmE, 1956). It 
acts through release of ACTH rather than having a direct effect on the adrenal gland 
(Gwimn,, 1965; Gwm-tn, et aL, 1967) and was one of the principal agents used to stimulate 
ACTH secretion prior to the discovery of cortieotropin releasing hormone (CRH) (L~cDON 
et al., 1965). Although a portion of vasopressin is co-localized and possibly co-released 
with CRH in certain cells of the parvoeellular region of the paraventricular nucleus of the 
hypothalamns, evidence from immunohistoehemical methods (SAwcm~K.~ et al., 1984) 
as well as differential models of stress (GraBS, 1986) suggest that regulation of vasopressin 
release can be independent of the release of CRF. Recently, investigators have identified 
receptors which are specific for arginine vasopressin on cells from the anterior pituitary 
(LuTz-BuCmZR and KOCH, 1983; KOCH and LuTz-BucrmR, 1985). Binding of vasopressin 
to these receptors has been demonstrated to stimulate ACTH secretion (SPn,~DI and NEGRO- 
VILtat, 1984). 
Three previous groups have used vasopressin to assess HPA axis function by measuring 
cortisol in patients with depressive disorders (J~acossoN et al., 1969; C_~atOLL, 1972; 
et al., 1985). The results of these investigations suggest that patients with depression have 
an abnormal cortisol response to vasopressin administration; however, the results are 
difficult to interpret. Two of these studies were uncontrolled and utilized lysine vasopressin, 
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which causes significant adversive side effects, rather than AVP (JAKoBSON et al., 1969; 
CARROLL, 1972). The third was controlled but suffered from small numbers and submaximal 
dosing of arginine vasopressin (AVP) (K_RAHN et al., 1985). 
Evidence supporting the hypothesis that HPA axis dysfunction in MDD may be the result 
of increased hypothalamic secretion of CRH is accumulating. In animal studies it has been 
shown that chronic administration of exogenous CRH causes increased secretion of ACTH, 
hypercortisolemia, and adrenal hypertrophy (PdvIER and VALE, 1983). There is also evidence 
to suggest that chronic stimulation with CRH may cause downregulation of the CRH 
receptor (RIVIER and VALE, 1983). In human studies NEM.ERO~ et  al. (1984) have found 
elevated concentrations of CRH in the cerebrospinal fluid of patients with MDD. HOLSBOER 
et al. (1984) and GOLD et aL (1984) have found blunted ACTH response to exogenous CRH 
stimulation in patients with MDD and have suggested that ACTH hyporesponse is caused 
by elevated levels of circulating corticosteroids in depressed patients (HOLSBOER et al., 1984a; 
GOLD et al., 1984). In two other studies, however, Holsboer failed to demonstrate a negative 
correlation between ACTH response to CRH and baseline cortisol levels in depressed 
patients (HoLSBOER et al., 1984b, 1985). As an alternative mechanism he proposes that 
pituitary corticotroph cells may be desensitized by "persistent excessive hypothalamic release 
of corticotropin-releasing factor." This alternative view is supported by Lopez who found 
no correlation between baseline cortisol levels and ACTH response to insulin hypoglycemia 
(LoPEz et al., 1987). 
There is strong data, then, to support chronic hypersecretion of CRH and subsequent 
downregulation of pituitary CRH receptors as a biologic abnormality in MDD. In this 
study we hypothesize that a substance such as AVP which stimulates specific receptors 
unattenuated by CRH levels would cause normal release of ACTH and subsequent increased 
cortisol release from chronically stimulated and hyperresponsive adrenals. 
METHODS 
Subjects  
Twenty-seven patients, 18 females and 9 males were recruited from the inpatient service 
of the University of Iowa Psychiatric Department. The mean age was 31.9 4- 10.0 (SD) 
with an age range of 21-58 yr. All met DSM-III criteria for a major depressive episode 
or bipolar affective disorder depressed type (AMERICAN PSYCHIATRIC ASSOCIATION, 1980). 
Diagnoses were confirmed by the NIMH Diagnostic Interview Schedule (DIS) (ROBINS, 
1981). Mean Hamilton score was 18.9 4- 5.0 (SD) (HAMILTON, 1960). 
Twenty-seven control subjects, 9 females and 18 males were recruited through an adver- 
tisement in a local paper. Their mean ages were 29.6 4- 8.4 yr (SD) with an age range 
of 20-52 yr. Control subjects were also screened with a DIS and excluded if an axis I 
diagnosis or antisocial personality disorder was indicated. Mean Hamilton score was 1.6 
4-0.96 (SD). 
After informed consent was obtained, all subjects underwent a medical history, physical 
examination, endocrine history, complete blood count, serum electrolytes, blood chemistry 
screen, thyroid screen, and electrocardiogram. Subjects with evidence of significant medical 
illness, history of substance abuse, or current use of medications known to interfere with 
the HPA axis were excluded (CARROLL et al., 1983). We did not alter the medication regimen 
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prescribed by ward physicians. Nineteen of  the patients were on tricyclic antidepressants, 
8 were on lithium, 1 was on monoamine oxidase inhibitor and 9 were on antipsychotic 
agents. Many of  our subjects participated in a larger study which included multiple endocrine 
tests and therefore several received an A C T H  stimulation test 24 h previous to the AVP 
challenge. As will be seen, there were no significant carry-over effects of  the A CTH  test. 
Arginine-vasopressin challenge 
All control subjects and depressed patients meeting the above criteria received 0.18 
pressor-units/kg body wt of  AVP intramuscularly at 4.00 p.m. Blood was drawn 
immediately prior to injection and at 15, 30, 45, 60, and 90 min after injection. Samples 
were collected in an EDTA containing tube and centrifuged at 4°C. Plasma was stored 
at - 7 0 ° C  until assay. Side effect profiles were obtained at the time of  each specimen 
retrieval. 
Dexamethasone suppression test (DST) 
The DST and AVP challenge test were separated by at least 48 h. Dexamethasone (1 
mg) was given orally at 2300 h. Blood was collected for cortisol determinations at 0800 
and 1600 h the following day. DST nonsuppression was defined as any postdexamethasone 
cortisol > 5.0 #g/dl. 
Based on the results of  dexamethasone suppression testing, patients with MDD were 
divided according to suppression status. Eight were non-suppressors (age 28.5 ± 9.0 SD; 
2 males, 6 females) and 19 were suppressors (age 32.1 ± 10.5 SD; 7 males, 11 females). 
The mean ± SD Hamilton scores for NS were 18.3 ± 4.6 and for suppressors 19.2 ± 
5.3. One control subject was a non-suppressor. 
Biochemical assay procedure 
The University of Iowa Medical Research Facility Laboratory has developed and validated 
its own radioimmunoassay (RIA) for ACTH and cortisol. A specific description of  these 
procedures can be found in Pror tLe t  al. (1985). 
In this study ACTH was measured in two separate assays. The majority of  the samples 
were assayed using the RIA described in ProrIL et aL (1985). The more recent samples were 
assayed by a new, more sensitive procedure in which the sensitivity for A CTH  
immunoreactivity in unextracted serum is 5 pg/ml.  Initial binding ranges from 30 to 40%. 
The intraassay C.V.s are 7.1%, 5.5%, and 4.8% for serum A CTH  concentrations of  10, 
59, and 408 pg/ml,  respectively. The corresponding interassay C.V.s are 6.2°70, 12.4%, 
and 11.5%, respectively. All samples f rom the same subject are run in the same assay. 
In order to compare results from the two assays a regression line was drawn and the predicted 
comparable values were assigned to the original assay results. 
The sensitivity of  the RIA for cortisol in unextracted serums is 0.5/~g/dl. The interassay 
C.V.s are 8.3 %, 6.6%, and 5.1% at serum cortisol concentrations of  2.7 ~g/dl, 11.7/~g/dl, 
and 23.6/zg/dl, respectively. The interassay C.V.s are 14.6%, 13.4%, and 16.7% at serum 
cortisol concentrations of  2.7, 11.2, and 23.6/zg/dl,  respectively. All samples f rom the 
same subject are run in the same assay. 
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Statistical analysis 
ACTH and cortisol response to AVP for patients with MDD (suppressors, S; non- 
suppressors, NS) and controls (C) at basal, 15, 30, 60, and 90 min; peak; mean maximal 
increase (A max); and integrated plasma levels (trapezoid rule) were compared using 
Student's t-tests or one-way ANOVAs. If the F-statistic was significant at the 0.05 level, 
the main effect means were compared with Tukey's studentized range test. 
The effects of age and sex were controlled for by analysis of covariance. The effect of 
psychiatric medications Were examined by grouping patients by psychiatric medications 
prescribed and comparing these groups to the remaining depressed patients using Student's 
t-test. 
RESULTS 
A C T H  response to A VP challenge 
There were no significant differences in ACTH among C, NS, and S for baseline, peak, 
A max levels, or integrated plasma levels. (Mean basal ACTH levels 4- SEM were 25.0 
4- 4.5 pg/ml for C, 19.2 4- 2.9 pg/ml for S, and 15.5 4- 3.6 for NS. Mean A ACTH 
was 15.5 4- 2.8 pg/ml for C, 12.0 4- 2.0 for S, and 17.0 4- 3.0 for NS) (Fig. 1.) 
As seen in Fig. 1 there is a trend for NS to have lower baseline ACTH values and lower 
subsequent levels at each time point. The A max values for NS and C, however, are quite 
similar. Nevertheless, with a N of 8 for the NS patients, a type II error is possible. 
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Fro. 1. ACTH response to 0.18 pressor units/kg arginine vasopressin in controls (O), in depressed dexamethasone 
non-suppressors ( 0 )  and suppressors (~) .  
Cortisol response to A VP challenge 
Mean (± SEM) baseline plasma cortisol levels were similar between the MDD patients 
and control subjects (MDD = 11.7 4- 0.7/~g/dl; C = 10.9 4- 0.5/zg/dl). The mean peak 
cortisol levels in the patients with MDD (20.8 4- 1.1 #g/dl) however was significantly greater 
than in the C group (17.2 4- 0.8/zg/dl) (t= 2.7, df=48.5, P <  0.01), and the mean A max 
cortisol level was also significantly greater in patients with MDD (MDD = 9.2 4- 0.95/~g/dl; 
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FIG. 2. Cortisol response to 0.18 pressor units/kg or arginine vasopressin in controls (©), in depressed 
dexamethasone non-suppressors (<)) and suppressors (A). 
C = 6.3 4- 0.6/zg/dl (t = - 2.5, df = 45.7, P < 0.02). The integrated plasma cortisol response 
curve was 1226 #g min/dl  in the MDD patients while it was 1057/~g min/dl  in the control 
subjects (t = - 2.2, df = 50.9, P < 0.05). 
When patients with MDD were divided into NS and S and three-group comparisons done, 
significant differences in mean baseline cortisol levels were found with NS (14.0 4- 1.7 
#g/dl) > S (10.7 4- 0.7) (F= 3.6, d f =  53, P < 0.05; Tukey, P < 0.05). The mean peak cortisol 
level in patients who were NS (22.0 4- 1.2 #g/dl) and S (20.4 4- 1.4 #g/d0  were nearly 
the same and probably represent maximal stimulation. (As mentioned above, mean peak 
cortisol values are significantly greater in patients than controls.) The A max cortisol levels 
of  the patients who were S (9.7 4- 1.2/~g/dl) was significantly greater than control subjects 
(F=3 .6 ,  d f =  53, P <  0.05, Tukey P <  0.05). The A max for NS patients was 7.9 4- 1.5 
#g/dl). 
When covariant analysis was used to evaluate the effects of  age, gender, and age-gender 
interactions on cortisol response to AVP, no interactions were found at the P < 0.05 level. 
A comparison of  ACTH and cortisol response to AVP in patients on and patients o f f  
tricyclic antidepressants, monomine oxidase inhibitors, lithium, and antipsychotics did not 
suggest any drug effect. AVP side effects were monitored throughout  the challenge test 
on all subjects and none reported marked subjective distress. A number of  subjects did 
report  mild, transient GI sensations, or demonstrated facial pallor noticed only by an 
external observer. Although it was felt that such mild effects would not interfere with our 
findings, a systematic analysis of  side effect profiles was done with control subjects and 
depressed patients compared using a standard chi square procedure. No differences in side 
effects profiles between patients and control subjects could be found. 
As previously mentioned several of  our subjects received an A C T H  challenge test 24 
h before the AVP was administered. In order to make certain there was no carry-over which 
might affect our results, mean A max cortisol and A CTH  levels were compared in a control 
population, 6 of  whom had received ACTH 24 h previously and 10 of  whom had not. 
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No significant differences were found and in fact cortisol mean A max was practically 
identical, 5.9 compared to 6.3. Mean A max ACTH tended to be smaller in subjects who 
had received ACTH, but this was not significant (P= 0.06). 
DISCUSSION 
One of the principal findings in our study is a similar ACTH response to AVP challenge 
in patients with MDD and control subjects. Although an inspection of Fig. 1 would suggest 
differences between NS and C, the standard errors of the mean ACTH values are quite 
high and statistical significance is not reached. This failure to attain significance may be 
in part due to the small N (8) in the NS group. It should be noted that the largest differences 
are found in basal ACTH between C and NS. This might be explained by the marked 
hypercortisolemia in the NS, causing negative feedback to ACTH. After vasopressin stimula- 
tion, however, ACTH response was quite uniform between C and NS. Although type II 
error is possible, this finding is distinctly different from the findings reported when 
pituitary corticot~ophs are stimulated by CRF (HoLssoER et al., 1984; GOLD et al., 1984). 
A normal ACTH response to AVP supports our original hypothesis. Although ACTH 
secretion may be blunted in response to CRF receptor downregulation, AVP receptors are 
functioning normally as demonstrated by normal ACTH secretion. Furthermore, this data 
would suggest that elevated levels of circulating glucocorticoids do not interfere with ACTH 
response to AVP, even though unstimulated ACTH levels may be attenuated. 
As might be expected from the recent reports of ACTH-cortisol dissociation (Sm~mM~ 
et al., 1984; PFom. et al., 1985) results of cortisol response to AVP do not parallel those 
of ACTH. Depressed patients demonstrate a clear augmentation of cortisol secretion in 
response to AVP stimulation. Such a response is not explained by differences in age or 
sex. A possible factor which could influence our findings is the potential effect medication 
could have on cortisol. Retrospective analysis of this possibility, however, suggests that 
psychotropic medications do not play a role in our findings. This conclusion is further 
supported by WYSI~M (1986) who found no difference in ACTH or cortisol response to 
AVP in normal controls before and after a 2-week trial of imipramine (150 mg/day). 
As mentioned previously three prior investigators have measured cortisol response to 
vasopressin in patients with affective disorders. The first reports of a vasopressin challenge 
test came in 1969 by JAKOBSON et al. 0969). They report a "hyperactive response" in 3 
of 16 patients. Control subjects were not employed and lysine vasopressin was used rather 
than arginine vasopressin. Further difficulties arise in interpreting these findings since they 
report than only 3 patients suffered from "endogenous" depression and 2 of their patients 
had their diagnosis changed to "schizophrenic psychosis with depressive features" during 
their hospitalization. 
In 1972 CARROLL (1972) reported a small subgroup of depressed patients who failed to 
respond with a cortisol response to 5 units of intravenous lysine vasopressin. This data 
is difficult to interpret since again LVP was used rather than AVP. The stress of 
gastrointestinal discomfort, nausea, and vomiting with LVP may have overridden the 
vasopressin effect alone and again no control subjects were included. 
The third study, ~.M~N et al. 0985) found that 3 out of 7 depressed patients failed to 
respond to the intravenous administration of 3 pressor units of arginine vasopressin. This 
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group was labeled "non-responders." We also found 5 subjects (both MDD and C) who 
did not have a meaningful cortisol response to our 0.18 pressor-unit/kg body-wt 
intramuscular AVP challenge (A max < 3 #g/dl). It seems possible that each individual 
has a threshold plasma vasopressin level which must be reached in order to mount a cortisol 
response. Since KgariN et al. (I985) used a very small stimulus (3 pressor units AVP) 
regardless of weight or size, this non-response group may simply have not achieved the 
threshold level. It is also possible that depressed individuals have a threshold value which 
is greater than normals. Such an increased value could explain Krahn's "non-responders." 
If these "non-responders" are excluded from Krahn's data, the mean z~ max of the depressed 
group is actually greater than the controls as in our data. 
A more recent investigation by yon B~VT.~BEN et al. (1985) did not directly test 
depressed patients, but rather challenged normal control subjects who had been pretreated 
with dexamethasone to inhibit ACTH release. In this study neither vasopressin nor CRH 
alone were able to produce a marked elevation of ACTH in pretreated subjects. However, 
if both peptides were administered in combination, a marked release of ACTH and cortisol 
was demonstrated, suggesting abnormalities in the regulation of both peptides in depression. 
Although not directly comparable, these results contrast with our finding of normal AVP 
functioning. Future research with larger numbers of dexamethasone non-suppressors will 
probably be necessary to resolve these issues. 
The fact that we find an increased cortisol response to AVP in depressed patients is 
consistent with other findings reported concerning HPA axis regulation in depression. 
A_~STEgD~ et aL (1983) reported that depressed patients have an augmented cortisol 
response to exogenous ACTH when compared to controls. The augmented cortisol response 
found in our study similarly represents an example of increased cortisol secretion in response 
to ACTH stimulation; however, in this case the adrenal is responding to endogenous rather 
than exogenous ACTH. Since stimulated ACTH levels were the same in both MDD patients 
and control subjects, the adrenals of the MDD patients must have been hyperresponsive 
to ACTH. Such augmented cortisol response to ACTH in patients with depression is 
understandable in light of the fact that patients with hypercortisolemia secondary to primary 
endocrine disease such as Cushing's disease also have augmented cortisol response to ACTH 
stimulation (BESSER and EDWARDS, 1972). 
In summary, our findings of normal ACTH response to AVP support the hypothesis 
that AVP receptors in pituitary corticotrophs are not downregulated as data suggest CRF 
receptors are. Our results also support the hypothesis that there is increased adrenal 
responsiveness to endogenous ACTH. Such a finding is consistent with those in other states 
of hypercortisolemia. These results are consistent with the theory that depression is related 
to chronic CRH hypersecretion and that stimulation with other ACTH secretagogues may 
shed further light on this possibility. 
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